Publicaciones en las que colabora con María José Carmena Sierra (9)

2005

  1. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue

    Gynecological Endocrinology, Vol. 20, Núm. 6, pp. 327-333

  2. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K

    Prostate, Vol. 63, Núm. 1, pp. 44-55

2004

  1. Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells

    Bioscience Reports, Vol. 24, Núm. 1, pp. 11-21

  2. PACAP expression and distribution in human breast cancer and healthy tissue

    Cancer Letters, Vol. 205, Núm. 2, pp. 189-195

  3. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells

    Regulatory Peptides, Vol. 119, Núm. 1-2, pp. 69-75

2003

  1. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue

    Peptides, Vol. 24, Núm. 6, pp. 893-902

  2. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal

    British Journal of Pharmacology, Vol. 139, Núm. 5, pp. 1050-1058

2002

  1. Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues

    Regulatory Peptides, Vol. 110, Núm. 1, pp. 9-15

2001

  1. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors

    Cellular Signalling, Vol. 13, Núm. 12, pp. 887-894